Chemical Characteristics of Platycodon grandiflorum and its Mechanism in Lung Cancer Treatment.
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK.
Cancer. 2025 Feb 1;131(3):e35738. doi: 10.1002/cncr.35738.
Impact of Lung Cancer Treatment on Cognitive Functioning.
van de Kamp HJ, Molder MT, Schulkes KJG, Stellingwerf M, van Elden LJR, van Lindert ASR, Hamaker ME.
Clin Lung Cancer. 2020 Mar;21(2):114-126.e3. doi: 10.1016/j.cllc.2019.06.006. Epub 2019 Jun 15.
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.
Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C.
Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18.
Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC).
Ashique S, Garg A, Mishra N, Raina N, Ming LC, Tulli HS, Behl T, Rani R, Gupta M.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):2769-2792. doi: 10.1007/s00210-023-02522-5. Epub 2023 May 23.
Nanoformulations in the treatment of lung cancer: current status and clinical potential.
Younis MA, Alsogaihi MA, Abdellatif AAH, Saleem I.
Drug Dev Ind Pharm. 2025 Sep;51(9):1088-1104. doi: 10.1080/03639045.2024.2437562. Epub 2024 Dec 11.
A Chinese classical prescription Qianjinweijing Decoction in treatment of lung cancer: An overview.
Liu P, Zhao Q, Xu Y, Ye J, Tan J, Hou J, Wang Y, Li J, Cui W, Wang S, Wang X.
Biomed Pharmacother. 2022 Dec;156:113913. doi: 10.1016/j.biopha.2022.113913. Epub 2022 Oct 26.
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
Wu X, Stabile LP, Burns TF.
Clin Lung Cancer. 2024 Sep;25(6):483-501. doi: 10.1016/j.cllc.2024.06.004. Epub 2024 Jun 10.
Application of Nano-Drug Delivery Systems in Lung Cancer Diagnosis and Treatment.
Tian L, Wang X, Chen Y, Wang W, Wu A, Jiang Q, Zhu H, Liu N, Pan J, Jin Y.
Biotechnol J. 2025 Oct;20(10):e70147. doi: 10.1002/biot.70147.
Pulmonary toxicity of systemic lung cancer therapy.
Long K, Suresh K.
Respirology. 2020 Nov;25 Suppl 2:72-79. doi: 10.1111/resp.13915. Epub 2020 Jul 29.
Nephrotoxicity of targeted therapy used to treat lung cancer.
Li Q, Lin J, Hao G, Xie A, Liu S, Tang B.
Front Immunol. 2024 Jul 4;15:1369118. doi: 10.3389/fimmu.2024.1369118. eCollection 2024.
